FIGHT TO LIVE

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2013–2014

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2014	—	3	1
2013	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TAYLOR, SYLLA & AGIN, LLP	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
No government targets were reported in these filings.

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	2
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bills Explicitly Cited (1)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2090113th Congress

Patient Choice Act of 2013

2013 · third_quarter · Firm: TAYLOR, SYLLA & AGIN, LLP

Open original LDA filing ↗

Cited source text and reported amounts

The Patient Choice Act - HR 2090 To obtain provisional approval of drugs in clinical trials for patients with terminal and life threatening illnesses. This legislation would allow individuals to obtain drugs outside of the scope of Phase I and Phase II clinical trials.

Client expense: — · Firm income: —

Matched citations: HR 2090

Source: Senate LDA

FIGHT TO LIVE — Lobbying Disclosure | Poliscope